China Resources Sanjiu Medical & Pharmaceutical Co (000999) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 reached ¥8.13 billion, up 18.62% year-over-year, while net profit attributable to shareholders fell 15.29% to ¥1.08 billion.

• Operating cash flow increased to ¥1.06 billion from ¥980 million year-over-year.

• Significant increases in sales and R&D expenses impacted profitability.

Financial highlights

• Revenue: ¥8.13 billion, up 18.62% year-over-year.

• Net profit attributable to shareholders: ¥1.08 billion, down 15.29% year-over-year.

• Basic and diluted EPS: ¥0.65, down from ¥0.77 year-over-year.

• Gross margin and operating profit margin declined due to higher costs.

• Cash and cash equivalents at period end: ¥3.20 billion, down 47.64% from prior year.

Outlook and guidance

• Management highlighted increased R&D and sales investments as strategic for future growth.

• No explicit forward guidance provided for the remainder of 2026.